<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002529</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000078385</org_study_id>
    <secondary_id>IBCSG-12-93</secondary_id>
    <secondary_id>EU-93015</secondary_id>
    <secondary_id>NCI-F93-0010</secondary_id>
    <nct_id>NCT00002529</nct_id>
  </id_info>
  <brief_title>Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer</brief_title>
  <acronym>12-93</acronym>
  <official_title>Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Breast Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Breast Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may
      fight breast cancer by blocking the uptake of estrogen. Drugs used in chemotherapy use
      different ways to stop tumor cells from dividing so they stop growing or die. Combining
      chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which
      treatment regimen is more effective for breast cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy during or
      after combination chemotherapy or hormone therapy alone in treating perimenopausal or
      postmenopausal women who have stage II or stage IIIA breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare overall survival and local and systemic disease-free survival produced
      by adjuvant chemoendocrine therapy with 4 courses of anthracycline/cyclophosphamide and
      concurrent vs. sequential tamoxifen (TMX) or toremifene (TOR) in peri- and postmenopausal
      women with node-positive breast cancer who are considered suitable for endocrine therapy
      alone. II. Evaluate these same endpoints in patients randomized to chemoendocrine therapy vs.
      endocrine therapy alone. III. Evaluate these same endpoints in patients randomized to TMX vs.
      TOR as the endocrine therapy agent. IV. Compare the quality of life of patients treated on
      these regimens. V. Compare the toxic effects of these regimens.

      OUTLINE: This is a randomized study. Patients are stratified by type of primary therapy and
      participating institution. Therapy must begin within 6 weeks of surgery. Patients in the
      first group receive doxorubicin (or epirubicin) and cyclophosphamide every 28 days for a
      total of 4 cycles and oral tamoxifen daily for 5 years, beginning day 1 of chemotherapy.
      Patients in the second group receive the same chemotherapy with oral tamoxifen initiated on
      day 8 of the fourth chemotherapy cycle and continued for 5 years. Patients in the third group
      receive oral tamoxifen daily for 5 years. Patients in the fourth group are treated the same
      as the first group, only tamoxifen is replaced by toremifene. Patients in the fifth group are
      treated the same as the second group, only tamoxifen is replaced by toremifene. Patients in
      the sixth group receive oral toremifene daily for 5 years. The timing of optional
      radiotherapy for patients with less than total mastectomy in each group is based on
      institutional policy; radiotherapy is administered for 5-6 weeks to the remaining breast
      tissue, chest wall, and lung. Patients are followed every 3 months for 1 year, every 6 months
      for 2 years, and yearly thereafter.

      PROJECTED ACCRUAL: 1,140 patients will be accrued over approximately 9 years, with 1
      additional year of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1993</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>17 years after randomization</time_frame>
    <description>Time from randomization to death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free and systemic disease-free survival.</measure>
    <time_frame>17 years from randomization</time_frame>
    <description>Time from randomization to recurrence, metastasis, appearance of a second primary tumor or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>17 years from randomization</time_frame>
    <description>Quality of life will be assessed using QL Questionnaires of IBCSG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>17 years after randomization</time_frame>
    <description>Assessment of toxicity according to standard criteria.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">452</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AC with concurrent tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC for 4 cycles with concurrent tamoxifen for 5 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC followed by tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC for 4 cycles followed by tamoxifen to 5 years from randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen alone for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC with concurrent toremifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC for 4 cycles with concurrent toremifene for 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC followed by toremifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AC for 4 cycles followed by toremifene to 5 years from randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toremifene alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toremifene alone for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days</description>
    <arm_group_label>AC with concurrent tamoxifen</arm_group_label>
    <arm_group_label>AC followed by tamoxifen</arm_group_label>
    <arm_group_label>AC with concurrent toremifene</arm_group_label>
    <arm_group_label>AC followed by toremifene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.</description>
    <arm_group_label>AC with concurrent tamoxifen</arm_group_label>
    <arm_group_label>AC followed by tamoxifen</arm_group_label>
    <arm_group_label>AC with concurrent toremifene</arm_group_label>
    <arm_group_label>AC followed by toremifene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
    <description>epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.</description>
    <arm_group_label>AC with concurrent tamoxifen</arm_group_label>
    <arm_group_label>AC followed by tamoxifen</arm_group_label>
    <arm_group_label>AC with concurrent toremifene</arm_group_label>
    <arm_group_label>AC followed by toremifene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Tamoxifen 20 mg daily.</description>
    <arm_group_label>AC with concurrent tamoxifen</arm_group_label>
    <arm_group_label>AC followed by tamoxifen</arm_group_label>
    <arm_group_label>Tamoxifen alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>toremifene</intervention_name>
    <description>Toremifene 60 mg daily.</description>
    <arm_group_label>AC with concurrent toremifene</arm_group_label>
    <arm_group_label>AC followed by toremifene</arm_group_label>
    <arm_group_label>Toremifene alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven stage T1-3, pN1, M0 carcinoma of the breast
        considered suitable for adjuvant treatment with endocrine therapy alone Estrogen receptor
        at least 10 fmol/mg cytosol protein or positive on immunohistochemical assay Potentially
        curative resection within 6 weeks of entry by one of the following: Total mastectomy with
        negative margins Breast-conserving procedure (lumpectomy or quadrantectomy) for tumors less
        than 5 cm Adequate re-resection or mastectomy within 4 weeks of initial surgery required if
        margins are positive after initial surgery Axillary clearance (not sampling) required at
        surgery, with at least 1 node positive upon histopathologic examination of at least 8 nodes
        Suspicious manifestations of metastatic disease (e.g., hot spots on bone scan, skeletal
        pain of unknown cause) must be proven benign No bilateral breast cancer Any mass in
        contralateral breast must be proven benign by biopsy

        PATIENT CHARACTERISTICS: Age: 70 and under Sex: Women only Menopausal status:
        Peri/postmenopausal, i.e.: More than 6 months since last normal menstrual period (LNMP)
        with no prior hysterectomy and no hormone replacement therapy (HRT) Prior hysterectomy and
        no HRT and either age greater than 55 or age 55 or less with postmenopausal LH, FSH, and E2
        levels On HRT and either age 50 or greater or LNMP more than 6 months prior to starting HRT
        Performance status: Not specified Hematopoietic: WBC greater than 4,000 Platelets greater
        than 100,000 Hepatic: Bilirubin less than 1.1 mg/dL (20 micromoles/L) AST less than 60 IU/L
        Renal: Creatinine less than 1.3 mg/dL (120 micromoles/L) Other: No nonmalignant systemic
        disease that would preclude protocol therapy or prolonged follow-up No psychiatric or
        addictive disorder that would preclude informed consent No prior or concurrent second
        malignancy except: Nonmelanomatous skin cancer Adequately treated in situ carcinoma of the
        cervix Geographically accessible for follow-up

        PRIOR CONCURRENT THERAPY: No prior therapy for breast cancer other than potentially
        curative surgery (see Disease Characteristics)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edda Simoncini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Spedali Civili di Brescia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle Mater Misericordiae Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>NSW 2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital, Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anti-Cancer Council of Victoria, Melbourne</name>
      <address>
        <city>Carlton South</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital, Perth</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Eugenio</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Adventist Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>5</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology, Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital, Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg (Goteborg)</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital des Cadolles, Neuchatel</name>
      <address>
        <city>Neuchatel</city>
        <zip>2000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - Saint Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A. Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer. 2009 Mar;45(4):561-71. doi: 10.1016/j.ejca.2008.10.011. Epub 2008 Dec 4.</citation>
    <PMID>19062268</PMID>
  </reference>
  <reference>
    <citation>Kenne Sarenmalm E, Odén A, Ohlén J, Gaston-Johansson F, Holmberg SB. Changes in health-related quality of life may predict recurrent breast cancer. Eur J Oncol Nurs. 2009 Dec;13(5):323-9. doi: 10.1016/j.ejon.2009.05.002. Epub 2009 Jul 12.</citation>
    <PMID>19596212</PMID>
  </reference>
  <reference>
    <citation>Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat. 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25.</citation>
    <PMID>18953651</PMID>
  </reference>
  <reference>
    <citation>Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008 Jun 20;26(18):3006-14. doi: 10.1200/JCO.2007.14.9336. Epub 2008 May 5.</citation>
    <PMID>18458044</PMID>
  </reference>
  <reference>
    <citation>Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber RD, Coates AS, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol. 2007 Apr;18(4):701-8. Epub 2007 Jan 20.</citation>
    <PMID>17237474</PMID>
  </reference>
  <reference>
    <citation>Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravaioli A; International Breast Cancer Study Group (IBCSG). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer. 2006 Feb 1;106(3):505-13.</citation>
    <PMID>16369994</PMID>
  </reference>
  <reference>
    <citation>International Breast Cancer Study Group, Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol. 2004 Dec;15(12):1749-59.</citation>
    <PMID>15550579</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2004</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Toremifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

